Investor Relations

Recent Event

CytoDyn Company Update

May 30, 2024 • 4:00 pm EDT

Latest Financial Results

Q3 2024

Quarter Ended Feb 29, 2024

Latest Annual Filing

For Year Ending May 31, 2023

Email Alerts

Stay informed and receive company updates straight to your inbox

Sign up today

Company Overview

CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.  CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells.  The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as graft-vs-host disease (GvHD) and NASH.

Investor Contact Information


CytoDyn Inc.
1111 Main Street
Suite 660
Vancouver, WA 98660
T: 360-980-8524
F: 360-799-5954

Transfer Agent

c/o Shareholder Services
P.O. Box 505002
Louisville, KY 40233-5002
T: 800-962-4284